Supernus Pharmaceuticals, Inc. Q2 FY2026 earnings call

• Merger Overview & Structure

  • Structured as an all-stock merger of equals, creating a leading diversified CNS-focused biopharmaceutical company
  • Supernus shareholders receive 1.5401 shares of Indivior common stock per Supernus share; Indivior will pay a $1 billion aggregate pre-closing dividend to its existing shareholders
  • Indivior shareholders will own ~56.5% of the combined company at closing, Supernus shareholders will own ~43.5% on a fully diluted basis
  • Combined board will have 4 directors from each company; Jack Khattar (Supernus CEO) will remain CEO of the combined company, the combined entity will retain the Supernus name and be headquartered in Rockville, Maryland
  • Transaction is expected to close in Q4 2026, pending shareholder and regulatory approvals and customary closing conditions

• Transaction Rationale & Key Benefits

  • Combines two complementary businesses from positions of strength: Supernus has a track record of successful acquisitions, pipeline development, and strong free cash flow generation, while Indivior completed its three-phase Action Agenda to accelerate Sublocate growth, simplify operations and strengthen its balance sheet
  • Expected to deliver $125 million in annual cost synergies, primarily from general and administrative redundancies and operational efficiencies, to be realized within 12 months of closing
  • Creates a stronger balance sheet, providing increased financial flexibility and capacity to pursue organic and business development growth opportunities that neither company could pursue independently
  • Diversifies the combined growth profile with 11 marketed medicines and 5 key growth products expected to grow into the 2030s, across four core therapeutic areas

• Post-Merger Priorities

  • Drive growth across the combined commercial portfolio, with continued investment in key growth products: Sublocate, Calibri, Zerzuve, GoCovrian and Onamco
  • Advance the combined pipeline of novel CNS product candidates, and replenish the pipeline through internal discovery and external business development
  • Pursue future business development and additional growth opportunities

On a trailing 12-month basis ending June 30, 2026:

• Supernus Pharmaceuticals: Total net revenue of $830 million, adjusted EBITDA of $150 million (18% adjusted EBITDA margin), $372 million in cash and no debt.
• Indivior Pharmaceuticals: Total net revenue of $1.3 billion, adjusted EBITDA of $613 million (46% adjusted EBITDA margin), net debt of $251 million, net leverage of 0.4x.
• Combined pro forma (including $125 million expected annual cost synergies): Total net revenue of ~$2.2 billion, adjusted EBITDA of $888 million (41% adjusted EBITDA margin), net debt of $878 million, net leverage of ~1x. By revenue contribution, Indivior's Sublocate is the largest single product contributor at approximately 44% of combined pro forma net revenue. The combined portfolio covers four therapeutic areas: addiction (led by Sublocate and Suboxone from Indivior), ADHD (led by Calibri from Supernus), depression (led by Zerzuve for postpartum depression from Supernus), and Parkinson's disease (led by GoCovrian and Onamco from Supernus).

No forward-looking guidance for post-closing financial performance was provided beyond the pro forma 12-month trailing metrics ending June 30, 2026. Management confirmed the $125 million annual cost synergy target, which is expected to be fully realized within 12 months of closing. No peak sales guidance was provided for Sublocate, though management noted that all key metrics for Sublocate are trending strongly, with durable long-term growth runway. Indivior has completed all three phases of its Action Agenda ahead of the merger, with all planned targets achieved.

Management noted that all forward-looking statements related to the proposed merger, expected synergies, and future growth are subject to risks and uncertainties, including those detailed in the companies' related SEC filings. Key uncertainties include: the need to obtain shareholder and regulatory approvals to close the transaction, the risk that expected cost synergies and growth benefits are not realized at the levels or timeline expected, and integration risk related to combining two independent organizations. No material operational failures were discussed during the call.

Q: What type of business development opportunities will the combined company pursue, what is its peak sales outlook for Sublocate, and how confident is management in consensus Indivior EBITDA estimates? / A: Management will maintain a disciplined, focused BD strategy centered on CNS, with women's health as a secondary focus area. The combined company's healthy pro forma adjusted EBITDA and more sustainable, higher-quality cash flows will give it greater capacity to pursue larger deals than either company could do independently. Management does not provide peak sales guidance for Sublocate, but notes all core metrics are trending strongly, with record new patient starts and stable 76% market share, and a long growth runway ahead as long-acting injectable utilization increases.

Q: How does the merger enhance the combined company's growth profile, and will there be revenue synergies from combining commercial and R&D operations? / A: The merger enhances the growth profile by creating a diversified portfolio of 5 growing products across four non-overlapping therapeutic areas. The larger financial resources of the combined company allow for greater investment to maximize the growth potential of existing products, and provide the capacity to acquire additional products that further accelerate total company growth, which neither firm could do independently. The $125 million cost synergy target comes from natural organizational redundancies, and management notes it has a strong track record of meeting synergy targets.

Q: What is the priority for business development by development stage, and what is the generic exclusivity runway for Sublocate? / A: The combined company will continue to prioritize commercial and mid-to-late stage assets for business development, consistent with Supernus' historical strategy. The company also has ongoing internal discovery efforts, augmented by capabilities from the 2025 Sage Therapeutics acquisition, and will disclose progress on those programs at a later date. For Sublocate, 12 Orange Book patents extend exclusivity from 2031 to 2038, and additional patent applications from a 2025 label update would extend exclusivity to 2042-2044. The product also has significant manufacturing complexity as a sterile long-acting injectable, which creates additional non-IP barriers to generic entry, and no generic paragraph IV filings have been submitted to date.

Q: How will the combined company leverage commercial synergies between the psychiatry/neuro and addiction treatment businesses, and how can the merger drive more patient adoption of OUD treatments? / A: There is minimal physician and market overlap between the addiction treatment business and Supernus' existing therapeutic areas, so the combined company will maintain four separate dedicated sales forces moving forward. For OUD and Sublocate, the large untapped market (only 10% penetration for long-acting injectables among diagnosed patients) means the biggest growth driver is continued investment in patient education and awareness to encourage more people with OUD to seek treatment, which is already driving strong growth in new patient starts.